8 / 31
Meta-analysis of 1
st
-line
anti-EGFR vs anti-VEGF in wt
RAS
mCRC
1.
Heinemann V, et al. Eur J Cancer 2016.
. Schwartzberg LS, et al. J Clin Oncol 2014. 3. Stintzing S, et al. J Clin Oncol 2014. 4. Heinemann V, et al. Ann Oncol 2014;.5. Heinemann V, et al.
Lancet Oncol 2014; 6. Venook AP, et al. J Clin Oncol 2014;32(Suppl 5):abstract LBA3; 7. Lenz H, et al. Ann Oncol 2014;25(Suppl 4):abstract 501O (
PEAK
2
Pre-specified
RAS
analysis
FIRE-3
3−5
Retrospective/exploratory
RAS
analysis
CALGB/SWOG 80405
6,7
Retrospective/exploratory
RAS
analysis
n = 170
n = 342
n = 526
WT
RAS
mCRC (n = 1038)
Study level meta-analysis
†
Endpoints:
OS (1
°
), PFS, ORR in WT
RAS
pts
Exploratory analysis:
OS in WT
KRAS
exon 2/MT other
RAS
pts
H2H studies of anti-EGFR vs anti-VEGF in 1
st
-line mCRC
1